基石藥業(02616.HK)披露治療肺癌藥物臨床研究數據
基石藥業-B(02616.HK)公布,在由國際肺癌研究協會舉辦的IASLC 2022年世界肺癌大會(WCLC)上,以口頭報告形式公布舒格利單抗作為鞏固治療在同步或序貫放化療後未發生疾病進展的、不可切除的III期非小細胞肺癌(NSCLC)患者的註冊性臨床試驗GEMSTONE-301研究的無進展生存期(PFS)最終分析結果。
PFS最終分析結果顯示,在同步或序貫放化療後未發生疾病進展的不可切除的III期NSCLC患者中,與安慰劑組相較,舒格利單抗組顯示出持續獲益。
目前,舒格利單抗已在中國獲批上市,用於治療同步或序貫放化療後未發生疾病進展的不可切除的III期NSCLC患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.